Teratogenic Effects Across Species: Insights from Animal Studies to Human Health Implications
Keywords:
Teratogenicity, Animal Models, CRISPR, Nanotechnology, Organ-on-chipAbstract
Teratogenicity refers to the ability of substances to cause developmental malformations in embryos or fetuses, posing significant challenges in pharmacology and toxicology, especially in the context of drug safety during pregnancy. Animal models have long been instrumental in studying the mechanisms of teratogenesis, providing insights into the molecular, genetic, and environmental factors that contribute to developmental defects. However, despite their utility, animal models have limitations due to species-specific differences in drug metabolism and development. Emerging technologies, including CRISPR gene-editing, nanotechnology, and organ-on-chip systems, offer promising alternatives that could enhance the accuracy of teratogenicity testing while reducing the ethical concerns associated with animal use. This paper explores the role of animal models in teratogenicity research, discusses the challenges of translating animal findings to human health implications, and highlights the potential of cutting- edge technologies to revolutionize the field, leading to better predictive accuracy and safer drug development
Downloads
Metrics
References
Wilson, J. G. (1977). Current status of teratology: General principles and mechanisms derived from animal studies. In J. G. Wilson & F. C. Fraser (Eds.), Handbook of Teratology (pp. 147–174). Plenum Press.
Szyf, M. (1985). Cell cycle-dependent regulation of eukaryotic DNA methylase level.
Journal of Biological Chemistry, 260(25), 13933–13939.
King, C., Rios, G., Green, M., & Tephly, T. (2000). UDP-glucuronosyltransferases.
Current Drug Metabolism, 1(2), 143–161.
Grandjean, P., & Landrigan, P. J. (2006). Developmental neurotoxicity of industrial chemicals. Lancet, 368(9553), 2167–2178.
Menegola, E., Di Renzo, F., & Vargesson, N. (2006). Postulated pathogenic pathways in triazole fungicide dysmorphogenic effects. Reproductive Toxicology, 22(2), 121–130.
Polifka, J. E., & Friedman, J. M. (2007). Clinical teratology: Identifying teratogenic risks in humans. Clinical Genetics, 56(6), 409–420.
Di Renzo, F., Menegola, E., & Di Giulio, C. (2007). Relationship between embryonic histonic hyperacetylation and axial skeletal defects in mice exposed to the three HDAC inhibitors apicidin, MS-275, and sodium butyrate. Toxicological Sciences, 97(1), 39–50.
Frias, J. L., & Gilbert-Barness, E. (2008). Human teratogens: Current controversies.
Advances in Pediatrics, 55, 171–211.
Gilbert-Barness, E. (2008). Human teratogens: Current controversies. Advances in Pediatrics, 55, 171–211.
Buhimschi, C. S., & Weiner, C. P. (2009). Medications in pregnancy and lactation: Part
2. Drugs with minimal or unknown human teratogenic effect. Obstetrics and Gynecology Clinics of North America, 31(2), 963–979.
Wells, P. G., McCallum, G. P., Chen, C. S., et al. (1997). Oxidative damage in chemical teratogenesis. Mutation Research, 414(1), 1–14.
Wells, P. G., McCallum, G. P., Chen, C. S., et al. (2005). Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. Toxicology and Applied Pharmacology, 207(2), 300–314.
Tiboni, G. M., & Kessel, M. (2006). Defining critical periods for itraconazole-induced cleft palate, limb defects, and axial skeletal malformations in the mouse. Toxicology Letters, 164(3), 308–319.
Vargesson, N. (2015). Thalidomide induced teratogenesis: History and mechanisms.
Birth Defects Research (Part C), 105(2), 140–156.
Koren, G., et al. (2017). Pharmacokinetics of drugs in pregnancy: Understanding placental transfer and metabolism. Reproductive Toxicology, 71, 55–62.
López-Rodríguez, D., et al. (2018). Maternal and fetal genetic and environmental factors influencing the susceptibility to teratogenicity. Reproductive Toxicology, 78, 184–190.
Baker, S. G., et al. (2020). Advances in human-specific models for developmental toxicity testing. Toxicology and Applied Pharmacology, 387, 114801.
Ingber, D. E. (2022). Human organs-on-chips for disease modelling, drug development and personalized medicine. Nature Reviews Genetics.
Li, X., Wang, H., You, X., & Zhao, G. (2025). Organoids-on-Chips Technology: Unveiling New Perspectives in Rare-Disease Research. International Journal of Molecular Sciences, 26(9), 4367.
[Frontiers Review]. (2024). In silico modelling of organ-on-chips: An overview.
Frontiers in Bioengineering and Biotechnology.
U.S. Government Accountability Office. (2025). Human organ-on-a-chip technologies: Benefits and current limitations. GAO Report.
[ScienceDirect]. (2025). AI-powered OoC and Digital Twin models to reduce animal testing. Drug Discovery Today, 30(2), 123–137
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
